Catalytic Antioxidant Program
The findings of research on natural antioxidant enzymes and antioxidant scavengers support the concept of antioxidants as a broad new class of therapeutic drugs, if certain limitations noted below could be overcome.
Our catalytic antioxidant program is designed to:
- Retain the catalytic mechanism and high antioxidant efficiency of the natural enzymes, and
- Create and develop stable and small molecule antioxidants without the limitations of superoxide dismutase(“SOD”) so that they:
- Have broader antioxidant activity,
- Have better tissue penetration,
- Have a longer life in the body, and
- Are not proteins, which are more difficult and expensive to manufacture.
We’ve created a class of small molecules that consume reactive oxygen and nitrogen species catalytically; that is, these molecules are not themselves consumed in the reaction. Our class of compounds is a group of manganoporphyrins (an anti-oxidant containing manganese) that retain the benefits of antioxidant enzymes, are active in animal models of disease and, unlike the body’s own enzymes, have properties that make them suitable drug development candidates.
Our most advanced compound, AEOL 10150, is a small molecule catalytic antioxidant that has shown the ability to scavenge a broad range of reactive oxygen species, or free radicals. As a catalytic antioxidant, AEOL 10150 mimics and thereby amplifies the body’s natural enzymatic systems for eliminating these damaging compounds. Because oxygen and nitrogen-derived reactive species are believed to have an important role in the pathogenesis of many diseases, we believe that Aeolus’ catalytic antioxidants and AEOL 10150 may have a broad range of potential therapeutic uses.
AEOL 10150 has shown efficacy in a variety of animal models, including Lung-ARS, nerve gas exposure, sulfur mustard and chlorine gas exposure, fibrotic pulmonary diseases, and ALS.
For a more detailed description of antioxidants see the section in our Education Center titled “Background on Antioxidants.”